“Stefan H. E. Kaufmann”的意思、由来-开放百科全书

Kaufmann is a German immunologist and microbiologist with focus on infection biology. He received his Dr. Rer. Nat. (PhD) at the University of Mainz in 1977 and his Habilitation in Immunology and Microbiology at the Free University Berlin in 1981. He was Professor at the University of Ulm from 1987 to 1998. Currently, he is Director of the Department of Immunology at the Max Planck Institute for Infection Biology in Berlin, for which he served as Founding Director in 1993. Member of the Max Planck Society since 1993. Since 1998 he is also Professor for Immunology and Microbiology at the Charité Berlin.

Career

Kaufmann has published more than 900 scientific original papers and review articles and according to the Institute for Scientific Information, he is one of the highly cited immunologists with more than 60,000 citations (Google Scholar) worldwide for the decade 1990 to 2000. His current scientific interest is focussed on the analysis of cell-mediated immunity against intracellular bacteria, the rational design and development of a better vaccine against tuberculosis as well as of biomarkers for reliable diagnosis of TB disease. Biomarker discovery is done in a multicentric approach with seven partner institutes in Africa with support from the Bill and Melinda Gates Foundation.^[4]^[5] His vaccine against tuberculosis is currently in phase II clinical trial assessment.^[6]^[7]^[8]^[9] A phase II/III vaccine trial to test prevention of tuberculosis recurrence is ongoing in India.^[10]^[11] Moreover, Kaufmann is actively involved in public awareness of immunology and infectious diseases.^[12] He is Past President and Honorary Member of the German Society of Immunology (DGfI), Past President of the European Federation of Immunological Societies (EFIS),^[13]^[14] and Past President of the International Union of Immunological Societies (IUIS).^[15] From 2010 to 2013 he was Member of the Board of the Global Alliance for Vaccines and Immunization (GAVI) as alternate representative of scientific and technical institutes. Since 2014 he is member of the Strategic Advisory Committee of the European and Developing Countries Clinical Trials Partnership (EDCTP). Kaufmann is member of the Board of Directors and of the Scientific Advisory Council of the Robert Koch Foundation (Robert-Koch-Stiftung e.V.), which annually awards the Robert Koch Prize and the Robert Koch Medal in gold. From 2013 to 2014 he was corresponding member of the Board of Trustees and since 2014 he is full member of the Board of Trustees for the Lindau Nobel Laureate meetings for the Lindau Nobel Laureate Meetings.^[16]

Kaufmann headed a team that developed a method of using defensis to combat anthrax.^[17]

Other activities

Prizes and honours

Kaufmann has received numerous rewards and honours for his scientific achievements in immunology of infectious diseases including:

In 2007, Kaufmann was conferred the title of Doctor Honoris Causa by the Université de la Mediterranée, Aix-Marseille II, France. In 2014 he received the Gardner Middlebrook Award. Fellow of the Royal College of Physicians of Edinburgh (FRCP Edin). He is Guest Professor, Tongji University, School of Medicine, Shanghai, China (since 2011), Honorary Professor, Universidad Peruana Cayetano Heredia, Lima, Peru (since 2012), and Visiting Professor, Peking Union Medical College, Beijing, China (since 2014).

Partial bibliography

External links

Videos

Latest Thinking: [https://lt.org/publication/can-biosignatures-be-used-develop-reliable-fast-and-low-cost-test-tuberculosis]

Latest Thinking: [https://lt.org/publication/how-can-we-improve-existing-vaccine-tuberculosis-combat-growing-number-multi-resistant]

References

1. ^
2. ^According to the Institute for Scientific Information
3. ^[Neugier und Bazillen, Cicero Magazin (Sabine Rosenbladt), p. 136-139, January 2011]
4. ^{{cite press release|url=http://www.mpg.de/english/illustrationsDocumentation/documentation/pressReleases/2005/pressRelease20050627/index.html |title=Global Commitment of Max Planck Researchers |publisher=Max Planck Society |date=2005-06-28 |accessdate=2010-06-19}}
5. ^Insciences
6. ^{{cite web|url=http://www.mpg.de/english/illustrationsDocumentation/documentation/pressReleases/2008/pressRelease20080910/index.html |title=Clinical trial for new tuberculosis vaccine |publisher=Max Planck Society |date=2008-09-11 |accessdate=2010-06-19}}
7. ^{{cite journal|url=http://content.nejm.org/cgi/content/extract/353/15/1624 |title=Rational Vaccine Development - A New Trend in Tuberculosis Control |doi=10.1056/NEJMcibr053426 |publisher=The New England Journal of Medicine |date=2005-10-13 |author=Gilla Kaplan, Ph.D. |volume= 353 |issue= 15 |accessdate=2010-06-19 |journal=New England Journal of Medicine |pages=1624–1625}}
8. ^{{cite journal | doi = 10.1126/science.334.6062.1488 | title = Taking a New Shot at a TB Vaccine | year = 2011 | last1 = Kupferschmidt | first1 = K. | journal = Science | volume = 334 | issue = 6062 | pages = 1488–90 | pmid = 22174226 }}
9. ^[Spritze gegen Schwindsucht, Der Spiegel 20/2012, Medizin, S. 118, 2012]
10. ^TB vaccine trial on adults begins in June. in: thehindu.com
11. ^Revamped, safer, and with greater punch. in: thehindu.com
12. ^How pandemics happen. Megan Murray, Nature Medicine, Book Review, Vol. 16 | No. 2 | February 2010, p. 159
13. ^http://www.immunology-info.org/index.php?filmid=0&play=true#projector
14. ^http://www.efis.org/
15. ^http://www.iuisonline.org/
16. ^ "Portraet - Mut, etwas zu machen"
17. ^Max Planck Society (2005, April 1). Defensins Neutralize Anthrax Toxin. ScienceDaily. Retrieved May 25, 2010, from [https://www.sciencedaily.com/releases/2005/03/050329133006.htm Science Daily News]
18. ^[https://www.worldhealthsummit.org/about-whs/leadership.html Council] World Health Summit.
19. ^{{Cite news|url=https://www.lindau-nobel.org/about/|title=About|work=The Lindau Nobel Laureate Meetings|access-date=2018-09-17|language=en-US}}